Hidroxicarbamida Hikma (Hydroxycarbamide)

Hydroxycarbamide, marketed as Hidroxicarbamida Hikma, is employed in the management of several blood disorders and certain cancers. It is prescribed when disease-modifying therapy is required to control abnormal cell proliferation.

• Sickle cell disease to reduce the frequency of painful crises.
• Chronic myelogenous leukemia as part of disease-modifying treatment.
• Polycythemia vera to lower elevated red blood cell counts.
• Essential thrombocythemia for platelet count control.
• Melanoma in selected therapeutic protocols.
• Off‑label use in other myeloproliferative neoplasms as directed by a specialist.

• Hydroxycarbamide inhibits the enzyme ribonucleotide reductase, which is essential for converting ribonucleotides to deoxyribonucleotides. By reducing the intracellular pool of deoxyribonucleotides, the drug limits DNA synthesis and replication in rapidly dividing cells, leading to cytoreduction of abnormal hematopoietic and malignant cell populations.

Hydroxycarbamide may cause a range of adverse reactions, some of which are dose‑related and reversible, while others require immediate medical attention.

Common

• Nausea, vomiting, or loss of appetite.
• Mild to moderate fatigue or weakness.
• Transient skin discoloration or hyperpigmentation.
• Low white blood cell (neutropenia) or platelet (thrombocytopenia) counts.
• Mild elevation of liver enzymes.

Serious

• Severe bone marrow suppression leading to pancytopenia.
• Acute hemolytic crisis in patients with glucose‑6‑phosphate dehydrogenase deficiency.
• Life‑threatening infections due to immunosuppression.
• Renal impairment or acute kidney injury.
• Severe cutaneous reactions such as Stevens‑Johnson syndrome.

Before initiating Hidroxicarbamida Hikma, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Baseline complete blood count and periodic monitoring during therapy.
• Assess renal and hepatic function prior to treatment and adjust as needed.
• Screen for glucose‑6‑phosphate dehydrogenase deficiency to avoid hemolysis.
• Use caution in pregnant or breastfeeding women; discuss risks versus benefits.
• Counsel patients on infection signs and advise prompt medical evaluation.
• Avoid concurrent use with other myelosuppressive agents unless medically justified.
• Discontinue if severe cytopenias or organ toxicity develop.

Hydroxycarbamide can interact with several drug classes, altering its efficacy or safety profile.

Avoid

• Concurrent administration with other cytotoxic chemotherapy agents that increase myelosuppression.
• Use of strong CYP2C9 inhibitors that may affect hydroxycarbamide metabolism.
• Live vaccines while immunosuppressed due to increased infection risk.

Use with caution

• Anticoagulants, as hydroxycarbamide may enhance bleeding tendencies.
• Allopurinol or other uric acid‑lowering agents, requiring monitoring for gout flares.
• NSAIDs, which can exacerbate renal impairment.
• Drugs that affect renal excretion, such as certain diuretics.
• Immunosuppressants, necessitating close hematologic surveillance.